Fig. 5
From: Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
The proportions of clinical trials on CAR-T cell therapy targets in solid tumors. BC: breast cancer; MSLN: mesothelin; GD2: ganglioside2; ROR: receptor tyrosine kinase like orphan receptor; CEA: carcinoembryonic antigen; MUC1: mucin 1; EGFR: epidermal growth factor receptor; HER2: human epidermal growth factor receptor 2; LCa: lung cancer; NY-ESO-1: New York esophageal squamous cell carcinoma-1; DLL3: delta-like ligand 3; PD-L1: programmed death-ligand 1; PCa: prostate cancer; NKG2DL: natural killer group 2 member D ligand; PSCA: prostate stem cell antigen; PSMA: prostate-specific membrane antigen; CRC: colorectal cancer; GC: gastric cancer; CLDN: claudin; HCC: hepatocellular carcinoma; GPC3: glypican-3; EC: esophageal cancer; PC: pancreatic cancer; GUCY2C: Guanylyl cyclase C; MEL: melanoma; VEGFR-2: vascular endothelial growth factor receptor 2; OC: ovarian cancer; ALPPL2: alkaline phosphatase placental-like 2; HNSCC: head and neck squamous cell carcinoma; OS: osteosarcoma; EWS: Ewing’s sarcoma; TC: thyroid cancer; ICAM-1: intercellular adhesion molecule-1; RCC: renal cell carcinoma; CAIX: carbonic anhydrase IX; CC: cervical cancer